Coronavirus Vaccine Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp, a New York-based clinical-stage biopharmaceutical company, is working to discover, license, acquire and develop small molecules and biologics to treat and prevent human disease.
Its portfolio is primarily made up of central nervous system and immunology product candidates, including vaccines. In the wake of the current pandemic, that has come to include coronavirus (COVID-19) vaccine candidates.
“The second quarter was highlighted by exciting progress for our lead immunology and central nervous system product candidates,” Tonix CEO Seth Lederman said in a recent statement. “We expect to have the first data from animal studies of our lead COVID-19 vaccine candidate, TNX-1800, in the fourth quarter of this year. TNX-1800 is a live attenuated vaccine based on our proprietary horsepox vector system that carries a gene encoding the Spike protein from SARS-CoV-2, the virus that causes COVID-19.”
This summer, Tonix announced research collaborations with Southern Research and Columbia University to study T-cell and antibody immune responses to the coronavirus in healthy volunteers who have recovered from COVID-19 or were exposed but remain asymptomatic.
News 
Market Data 
Discover 
